Tuane C R G Vieira

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4107171/publications.pdf

Version: 2024-02-01

22 papers 891 citations

15 h-index 713013 21 g-index

22 all docs 22 docs citations

times ranked

22

1019 citing authors

#	Article	IF	Citations
1	Nucleic acid actions on abnormal protein aggregation, phase transitions and phase separation. Current Opinion in Structural Biology, 2022, 73, 102346.	2.6	12
2	Phase separation of p53 precedes aggregation and is affected by oncogenic mutations and ligands. Chemical Science, 2021, 12, 7334-7349.	3.7	48
3	Rabbit PrP Is Partially Resistant to in vitro Aggregation Induced by Different Biological Cofactors. Frontiers in Neuroscience, 2021, 15, 689315.	1.4	3
4	Viral and Prion Infections Associated with Central Nervous System Syndromes in Brazil. Viruses, 2021, 13, 1370.	1.5	8
5	Challenges and Advances in Antemortem Diagnosis of Human Transmissible Spongiform Encephalopathies. Frontiers in Bioengineering and Biotechnology, 2020, 8, 585896.	2.0	16
6	Second-Generation RT-QuIC Assay for the Diagnosis of Creutzfeldt-Jakob Disease Patients in Brazil. Frontiers in Bioengineering and Biotechnology, 2020, 8, 929.	2.0	8
7	The use of second generation RTâ€QuIC assay for the diagnosis of Creutzfeldt Jakob disease patients in Brazil. Alzheimer's and Dementia, 2020, 16, e042232.	0.4	0
8	The Status of p53 Oligomeric and Aggregation States in Cancer. Biomolecules, 2020, 10, 548.	1.8	40
9	Modulation of p53 and prion protein aggregation by RNA. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2019, 1867, 933-940.	1.1	17
10	Liquid-liquid phase transitions and amyloid aggregation in proteins related to cancer and neurodegenerative diseases. Advances in Protein Chemistry and Structural Biology, 2019, 118, 289-331.	1.0	50
11	In Vitro Prion Amplification Methodology for Inhibitor Screening. Methods in Molecular Biology, 2019, 1873, 305-316.	0.4	3
12	Prion protein-coated magnetic beads: Synthesis, characterization and development of a new ligands screening method. Journal of Chromatography A, 2015, 1379, 1-8.	1.8	12
13	The aggregation of mutant p53 produces prion-like properties in cancer. Prion, 2014, 8, 75-84.	0.9	90
14	High-Pressure Chemical Biology and Biotechnology. Chemical Reviews, 2014, 114, 7239-7267.	23.0	177
15	Heparin binding confers prion stability and impairs its aggregation. FASEB Journal, 2014, 28, 2667-2676.	0.2	57
16	The role of RNA in mammalian prion protein conversion. Wiley Interdisciplinary Reviews RNA, 2012, 3, 415-428.	3.2	26
17	Heparin Binding by Murine Recombinant Prion Protein Leads to Transient Aggregation and Formation of RNA-Resistant Species. Journal of the American Chemical Society, 2011, 133, 334-344.	6.6	56
18	Experimental approaches to the interaction of the prion protein with nucleic acids and glycosaminoglycans: Modulators of the pathogenic conversion. Methods, 2011, 53, 306-317.	1.9	24

#	Article	IF	CITATIONS
19	PrP interactions with nucleic acids and glycosaminoglycans in function and disease. Frontiers in Bioscience - Landmark, 2010, 15, 132.	3.0	30
20	Ligand Binding and Hydration in Protein Misfolding: Insights from Studies of Prion and p53 Tumor Suppressor Proteins. Accounts of Chemical Research, 2010, 43, 271-279.	7.6	104
21	Prion Protein Complexed to N2a Cellular RNAs through Its N-terminal Domain Forms Aggregates and Is Toxic to Murine Neuroblastoma Cells. Journal of Biological Chemistry, 2008, 283, 19616-19625.	1.6	78
22	Acharan sulfate, the new glycosaminoglycan from Achatina fulica Bowdich 1822. FEBS Journal, 2004, 271, 845-854.	0.2	32